162 related articles for article (PubMed ID: 21604432)
1. [How to improve the histopathological diagnosis of hepatocellular carcinoma in daily practice?].
Honsová E; Lodererová A
Cesk Patol; 2011 Apr; 47(2):40-3. PubMed ID: 21604432
[TBL] [Abstract][Full Text] [Related]
2. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.
Roskams T; Kojiro M
Semin Liver Dis; 2010 Feb; 30(1):17-25. PubMed ID: 20175030
[TBL] [Abstract][Full Text] [Related]
3. Liver biopsy in the diagnosis of hepatocellular carcinoma.
Wanless IR
Clin Liver Dis; 2005 May; 9(2):281-5, vii. PubMed ID: 15831273
[TBL] [Abstract][Full Text] [Related]
4. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
Nassar A; Cohen C; Siddiqui MT
Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
[TBL] [Abstract][Full Text] [Related]
5. Pathological diagnosis at early stage: reaching international consensus.
Kojiro M
Oncology; 2010 Jul; 78 Suppl 1():31-5. PubMed ID: 20616581
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of glypican-3 for hepatocellular carcinoma on liver needle biopsy.
Wang FH; Yip YC; Zhang M; Vong HT; Chan KI; Wai KC; Wen JM
J Clin Pathol; 2010 Jul; 63(7):599-603. PubMed ID: 20501450
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3 immunostaining significantly improves histological diagnosis of hepatocellular carcinoma.
Honsová E; Lodererová A; Franková S; Oliverius M; Trunecka P
Cas Lek Cesk; 2011; 150(1):37-40. PubMed ID: 21400962
[TBL] [Abstract][Full Text] [Related]
8. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma.
Di Tommaso L; Destro A; Seok JY; Balladore E; Terracciano L; Sangiovanni A; Iavarone M; Colombo M; Jang JJ; Yu E; Jin SY; Morenghi E; Park YN; Roncalli M
J Hepatol; 2009 Apr; 50(4):746-54. PubMed ID: 19231003
[TBL] [Abstract][Full Text] [Related]
9. Stromal morphological changes and immunophenotypic features of precancerous lesions and hepatocellular carcinoma.
Chen D; Li Z; Zhu W; Cheng Q; Song Q; Qian L; Zhu JY
J Clin Pathol; 2019 Apr; 72(4):295-303. PubMed ID: 30610005
[TBL] [Abstract][Full Text] [Related]
10. From large to small: the immunohistochemical panel in the diagnosis of early hepatocellular carcinoma.
Vasuri F; Malvi D; Bonora S; Fittipaldi S; Renzulli M; Tovoli F; Golfieri R; Bolondi L; D'Errico A
Histopathology; 2018 Feb; 72(3):414-422. PubMed ID: 28881044
[TBL] [Abstract][Full Text] [Related]
11. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma.
Cao W; Sharma M; Imam R; Yu J
Am J Clin Pathol; 2019 Oct; 152(5):647-655. PubMed ID: 31305883
[TBL] [Abstract][Full Text] [Related]
12. Analytical histopathological diagnosis of small hepatocellular nodules in chronic liver disease.
Nakanuma Y; Hirata K; Terasaki S; Ueda K; Matsui O
Histol Histopathol; 1998 Oct; 13(4):1077-87. PubMed ID: 9810504
[TBL] [Abstract][Full Text] [Related]
13. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
14. [Selective deposition of agrin in the microvasculature of hepatocellular carcinoma: aspects in pathogenesis and differential diagnosis].
Tátrai P
Magy Onkol; 2008 Dec; 52(4):379-83. PubMed ID: 19068466
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of absent ductular reaction at hepatocellular-stromal boundaries in early stage hepatocellular carcinoma].
Zhang Q; Ma Z; Xin Q; Liu GQ; Liu BB; Gao YT; Zhang CS; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2013 Dec; 21(12):924-8. PubMed ID: 24636295
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic role of glypican 3 and CD34 for differentiating hepatocellular carcinoma from nonmalignant hepatocellular lesions.
Enan ET; El-Hawary AK; El-Tantawy DA; Abu-Hashim MM; Helal NM
Ann Diagn Pathol; 2013 Dec; 17(6):490-3. PubMed ID: 24012547
[TBL] [Abstract][Full Text] [Related]
17. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of hepatocellular carcinoma: role of tumor markers and liver biopsy.
Gonzalez SA; Keeffe EB
Clin Liver Dis; 2011 May; 15(2):297-306, vii-x. PubMed ID: 21689614
[TBL] [Abstract][Full Text] [Related]
19. Golgi protein 73, not Glypican-3, may be a tumor marker complementary to α-Fetoprotein for hepatocellular carcinoma diagnosis.
Wang Y; Yang H; Xu H; Lu X; Sang X; Zhong S; Huang J; Mao Y
J Gastroenterol Hepatol; 2014 Mar; 29(3):597-602. PubMed ID: 24236824
[TBL] [Abstract][Full Text] [Related]
20. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis.
Llovet JM; Chen Y; Wurmbach E; Roayaie S; Fiel MI; Schwartz M; Thung SN; Khitrov G; Zhang W; Villanueva A; Battiston C; Mazzaferro V; Bruix J; Waxman S; Friedman SL
Gastroenterology; 2006 Dec; 131(6):1758-67. PubMed ID: 17087938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
